Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer

<table>Survival difference of patients with PCI <svg height="10.15" id="M18" style="vertical-align:-0.546pt" version="1.1" viewbox="0 0 14.825 10.15" width="14.825" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,9.413)"><path d="M531 71l-474 214v50l474 215v-56l-416 -184l416 -183v-56zM531 -40h-474v50h474v-50z" id="x2264"></path></g>
</svg> 6 and those with PCI <svg height="10.15" id="M19" style="vertical-align:-0.546pt" version="1.1" viewbox="0 0 14.825 10.15" width="14.825" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,9.413)"><path d="M531 285l-474 -214v56l416 183l-416 184v56l474 -215v-50zM531 -40h-474v50h474v-50z" id="x2265"></path></g>
</svg> 7.</table>

International Journal of Surgical Oncology

fig4

Figure 4

Figure 4: Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer 

Figure 4 | Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer 